True North Labs

Author: labstruenorth@gmail.com

  • Retatrutide: 5 Promising Facts About the Next-Generation Weight-Loss Peptide

    Retatrutide has become one of the most talked-about names in metabolic research, and for good reason. This investigational peptide is designed to activate three different hormone receptors at once—GLP-1, GIP, and glucagon—giving it a broader mechanism of action than many existing options. Researchers believe this triple-action approach could translate into more robust outcomes for weight management and related metabolic health markers.

    Early and mid-stage clinical trial data have shown encouraging weight-reduction results, which is part of why the compound has earned nicknames like the “trillion-dollar” drug in industry coverage. While that label speaks more to market potential than medical outcomes, it reflects genuine optimism among scientists and investors about how transformative this class of peptides could be for people living with obesity, a condition linked to numerous downstream health risks.

    Beyond weight loss itself, researchers are interested in retatrutide’s potential ripple effects on metabolic health more broadly—including markers tied to blood sugar regulation and cardiovascular risk factors. The multi-receptor design is part of a larger trend in peptide science: rather than targeting a single pathway, newer compounds are engineered to work across multiple systems simultaneously, potentially offering more comprehensive benefits from a single treatment.

    It’s important to note that retatrutide is still investigational and continues to move through the clinical trial process. That means dosing protocols, long-term safety data, and eventual regulatory approval are all still being established. Still, the level of interest surrounding this peptide underscores how quickly the field of metabolic and weight-management peptides is evolving, with each new compound building on lessons learned from earlier GLP-1 therapies.

    For the broader peptide research community, retatrutide represents an exciting proof-of-concept: that thoughtfully designed, multi-target peptides may be able to achieve outcomes that single-pathway drugs cannot. As trials progress, many in the field will be watching closely to see whether this next generation of therapies can deliver on its considerable promise.

    This article is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before considering any treatment.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: 5 Things to Know About Retatrutide, the “Trillion-Dollar” Drug – AJMC

  • FDA-Approved Peptide Therapies Offer New Options for Weight Management

    FDA-Approved Peptide Therapies Offer New Options for Weight Management

    Peptide-based therapies are increasingly recognized by regulators as viable tools for supporting weight management, with the U.S. Food and Drug Administration having approved several injectable peptide medications designed to help patients reduce body weight and improve related metabolic markers. These approvals mark a significant milestone for the peptide field, which has moved from experimental status to mainstream clinical use in just a few years.

    The peptides in question work by mimicking natural hormones involved in appetite regulation and blood sugar control, helping patients feel fuller for longer and supporting healthier eating patterns. Because these medications are grounded in the body’s own signaling systems, they represent a more targeted approach compared to older weight-loss drugs, and clinical trials supporting their approval demonstrated meaningful results for many participants.

    FDA approval is a rigorous process that requires extensive data on both safety and effectiveness, so each green light for a new peptide therapy signals that regulators found the evidence compelling enough to make these options available to the public. This also opens the door for insurance coverage conversations and broader access, which can make these treatments more attainable for patients working with their healthcare providers to manage weight-related health concerns.

    Beyond the immediate benefit to patients, these approvals help validate the broader peptide research ecosystem, encouraging further investment and scientific exploration into how peptides might address other health challenges. As more peptide candidates move through clinical trials, the success of these weight-management therapies offers an encouraging blueprint for future innovation in the space.

    This article is for informational purposes only and is not medical advice. Anyone considering a peptide-based treatment should consult a qualified healthcare provider.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: fda approved peptides for weight loss – polskieradio.pl

  • Retatrutide Shows Impressive Weight Loss Results in Patients with Obesity and Type 2 Diabetes

    Retatrutide Shows Impressive Weight Loss Results in Patients with Obesity and Type 2 Diabetes

    Exciting new data from clinical trials of retatrutide, an investigational triple-agonist peptide, demonstrates weight loss of up to 20.8% in patients managing both obesity and type 2 diabetes—two conditions that have historically been challenging to address simultaneously with a single treatment approach.

    Retatrutide works by targeting three distinct hormone receptors involved in metabolism and appetite regulation, a mechanism that builds on the success of earlier dual-agonist peptides. The reported results are particularly encouraging because patients with type 2 diabetes often experience more modest weight loss responses to treatment compared to those without diabetes, due to the complex interplay between blood sugar regulation and body weight. Achieving over 20% weight reduction in this population represents a meaningful step forward for a group that frequently faces limited options.

    These findings add to a growing body of evidence suggesting that next-generation peptide therapies may offer substantial benefits for people managing the dual burden of obesity and diabetes. Effective weight management in this population can contribute to improved blood sugar control, reduced strain on the cardiovascular system, and better overall metabolic health. The scale of weight loss reported here is notable when compared to many existing treatment options, highlighting the potential of multi-receptor targeting as a therapeutic strategy.

    Researchers and clinicians continue to study retatrutide’s safety profile and long-term outcomes as part of its ongoing clinical development. The peptide field has seen rapid innovation in recent years, with triple-agonist compounds like retatrutide representing the latest evolution in a lineage of treatments that began with single-hormone therapies and progressed to dual-action peptides. Continued trial progress offers hope for more personalized and effective treatment options for people living with both obesity and type 2 diabetes.

    As research progresses, the peptide community will be watching closely for additional data on durability of results and broader patient populations. This is for informational purposes only and not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D – AJMC

  • New CAR T-Cell Trial Targets Childhood Rhabdomyosarcoma

    Researchers have launched a new clinical trial exploring an innovative immune-based treatment for rhabdomyosarcoma (RMS), the most common soft tissue cancer in children. The study, registered on ClinicalTrials.gov, will evaluate a therapy known as FGFR4-CAR T cells in patients aged 3 to 39 whose cancer has returned or not responded to at least two rounds of standard treatment.

    The approach relies on chimeric antigen receptor (CAR) T-cell technology, a form of personalized immunotherapy that has already shown success in certain blood cancers. In this trial, each participant’s own T cells—key immune system fighters—will be collected through a process called apheresis and sent to a lab, where they will be genetically modified to recognize FGFR4, a protein commonly found on the surface of rhabdomyosarcoma cells. Once these engineered cells are ready, they will be infused back into the patient’s bloodstream, where the hope is that they will seek out and attack tumor cells carrying this specific marker.

    What makes this research particularly encouraging is its focus on a difficult-to-treat pediatric cancer population: children and young adults whose RMS has proven resistant to conventional therapies. For families facing limited options after standard treatment has failed, a trial exploring a targeted, cell-based therapy represents a meaningful step forward. CAR T-cell therapies have already transformed outcomes for some blood cancers, and extending this technology to solid tumors like rhabdomyosarcoma reflects the growing versatility and promise of engineered immune cell treatments.

    The study design also reflects a thoughtful, thorough approach to patient safety and long-term understanding. Participants will undergo careful screening, including imaging, blood work, and heart function tests, before treatment. After receiving the CAR T cells, they will be closely monitored for effects on their tumors and any potential side effects, with follow-up visits continuing for five years and long-term tracking extending to fifteen years total. This extended observation period underscores the research team’s commitment to fully understanding both the benefits and safety profile of this novel therapy over time.

    While it will take time before results are known, the initiation of this trial is a hopeful sign for the pediatric oncology community. It represents continued innovation in harnessing the body’s own immune system to fight cancers that have been historically challenging to treat, and it offers a new avenue of hope for young patients and their families.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

  • New Phase I Trial Launches to Evaluate AUBE00 for Advanced Solid Tumors

    New Phase I Trial Launches to Evaluate AUBE00 for Advanced Solid Tumors

    A new international clinical trial has begun evaluating AUBE00, an investigational therapy being studied for its potential to treat locally advanced or metastatic solid tumors. Registered on ClinicalTrials.gov, this first-in-human, open-label Phase I study marks an important early step in exploring the compound’s ability to help patients facing difficult-to-treat cancers.

    The trial will enroll approximately 90 to 130 participants across multiple centers and countries, allowing researchers to gather diverse data on how the therapy performs in real-world clinical settings. Investigators will assess key factors including safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary signs of anti-tumor activity. This comprehensive early-phase design reflects a thorough, methodical approach to understanding how AUBE00 behaves in the human body before any larger efficacy trials are considered.

    Phase I trials like this one are foundational to the drug development process. They provide crucial information about dosing, safety margins, and how the body processes a new treatment. For patients with advanced solid tumors, participation in such trials can offer access to novel therapeutic approaches when standard treatment options may be limited, while also contributing valuable scientific knowledge that could benefit future patients.

    The multinational, multicenter design of this study is particularly encouraging, as it suggests a coordinated global effort to accelerate understanding of this investigational therapy. Collaboration across research sites often speeds up recruitment and allows for more robust data collection, which can help bring promising treatments closer to patients who need them.

    While it will take time before results from this study are available, the initiation of this trial represents a hopeful step forward in oncology research. True North Labs will continue to follow developments in this space and share updates as they emerge. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Study of AUBE00 in Patients With Solid Tumors

  • New Clinical Trial Explores Combining Quad Shot Radiotherapy With Immunotherapy for Lung Cancer

    A newly registered clinical trial is investigating an innovative approach to treating stage II-III non-small cell lung cancer (NSCLC) by combining a novel radiotherapy technique with immunotherapy and chemotherapy before surgery. The study, listed on ClinicalTrials.gov, aims to build on the current standard of care—which already combines immunotherapy and chemotherapy prior to surgery—by adding a radiation technique known as Quad Shot (QS) radiotherapy to the treatment regimen.

    Unlike conventional daily radiation therapy, Quad Shot radiotherapy is delivered in short, high-dose cycles designed to stimulate the immune system’s ability to recognize and attack cancer cells while potentially causing less toxicity than standard radiation schedules. Researchers believe that pairing this approach with Tislelizumab, an immune checkpoint inhibitor, and standard platinum-based chemotherapy could improve outcomes for patients preparing for surgical removal of their tumors.

    The primary goal of the trial is to determine whether this three-part combination therapy can help achieve a pathological complete response (pCR)—meaning no detectable cancer cells remain in the tumor tissue when examined under a microscope after surgery. This is considered a strong indicator of treatment effectiveness and is associated with better long-term outcomes in many cancer types. Investigators will also closely monitor safety, side effects, and how well patients tolerate the treatment leading up to their surgical procedures.

    While the trial is small, enrolling approximately 12 patients, it represents part of a broader and encouraging trend in oncology: the thoughtful integration of radiotherapy with immunotherapy to enhance the body’s natural immune response against tumors. If successful, this approach could offer patients with NSCLC an additional tool to reduce residual disease before surgery, potentially improving surgical outcomes and long-term prognosis.

    Early-phase studies like this one are essential steps in advancing cancer care, helping researchers understand how new combinations of established therapies might work better together than any single treatment alone. As with all investigational treatments, results from this study will need to be confirmed through further research before broader clinical adoption. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer

  • FDA Advisory Committee Signals Favorable Stance on Compounded Peptides

    The peptide community received encouraging news this week as the U.S. Food and Drug Administration’s advisory committee on compounding pharmacies opened its highly anticipated meeting with discussions that appeared favorable toward peptide-based compounded medications. According to reporting from Fierce Pharma, the first day of proceedings saw peptides positioned in a positive light among the various substances under review.

    Advisory committee meetings like this one play a crucial role in shaping how the FDA approaches oversight of compounded medications, including popular peptide therapies that patients and practitioners have increasingly relied upon. A favorable reception at this stage is a meaningful signal for the broader peptide community, potentially supporting continued patient access to these compounded formulations through licensed pharmacies.

    For patients who have found value in compounded peptide therapies, this development offers reassurance that regulators are taking a thoughtful, evidence-based approach rather than moving toward blanket restrictions. Compounding pharmacies serve an important function in the healthcare system, often providing personalized formulations and dosing options that may not be available through standard commercial channels.

    The advisory committee process itself reflects a rigorous, deliberative approach by the FDA, one that weighs safety, efficacy, and manufacturing quality alongside patient access considerations. The fact that peptides were viewed favorably during initial discussions suggests that the scientific and clinical data presented resonated positively with committee members, a good sign for continued availability of these compounds.

    As the committee proceedings continue, the peptide industry and patient advocates will be watching closely for further developments. True North Labs will continue to monitor this story and provide updates as more information becomes available from subsequent meeting days.

    This article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider regarding any questions about peptide therapies or treatment options.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm – Fierce Pharma

  • New Approach to Measuring C-Peptide Could Improve Type 1 Diabetes Trials

    New Approach to Measuring C-Peptide Could Improve Type 1 Diabetes Trials

    Researchers are exploring a refined statistical approach to measuring C-peptide levels over time that could make clinical trials for type 1 diabetes (T1D) more efficient and informative. C-peptide, a byproduct of insulin production, serves as a key biomarker for how much insulin-producing capacity a person with T1D still has. According to work highlighted by biostatistician Samuel Shangwu Wu, PhD, and reported by AJMC, using a longitudinal endpoint that tracks C-peptide changes over the full course of a trial—rather than relying on a single snapshot measurement—may better capture the true impact of emerging therapies.

    This shift in trial design matters because many promising T1D treatments, including various peptide-based and immunotherapy approaches, aim to slow or preserve the body’s remaining insulin production, especially in the early stages after diagnosis. Traditional endpoints that measure C-peptide at just one or two time points can miss meaningful trends or fluctuations, potentially underselling a therapy’s real benefit or requiring larger, more expensive trials to detect an effect. A longitudinal approach, by contrast, uses repeated measurements to build a fuller picture of how a treatment influences insulin-producing beta cell function throughout the study period.

    For patients and families affected by type 1 diabetes, this kind of methodological advancement is good news even though it isn’t a treatment itself. Better trial design means researchers can potentially detect real treatment effects with fewer participants and shorter timelines, which historically translates into faster answers about whether a therapy works. It could also help scientists more accurately compare the effectiveness of different interventions, from novel peptides to immune-modulating drugs, giving the field clearer guidance on which approaches deserve further investment and development.

    This kind of statistical innovation reflects a broader trend in T1D research: as more therapies enter the pipeline aimed at preserving beta cell function, especially in newly diagnosed patients, having precise and sensitive tools to measure success becomes increasingly important. Improved endpoints like this one could help accelerate the path from promising early trial results to therapies that meaningfully extend the period during which a person’s body still produces some of its own insulin.

    While this development is centered on trial methodology rather than a new drug or therapy, it represents the kind of behind-the-scenes progress that often paves the way for faster, more reliable breakthroughs down the road. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Longitudinal C-Peptide End Point Could Strengthen T1D Trial Design: Samuel Shangwu Wu, PhD – AJMC

  • TwoStep Therapeutics Secures $62.5 Million Series A and FDA IND Clearance for Novel Peptide-Drug Conjugate

    TwoStep Therapeutics has announced two major milestones that signal strong momentum for its peptide-based drug development platform: an oversubscribed $62.5 million Series A financing round and FDA clearance of an Investigational New Drug (IND) application for its lead peptide-drug conjugate candidate. The dual announcement marks an important step forward for a company positioning itself at the forefront of next-generation peptide therapeutics.

    The financing round, described as oversubscribed, suggests significant investor confidence in TwoStep’s scientific approach and pipeline potential. Peptide-drug conjugates represent an increasingly promising area of biomedical research, combining the targeting precision of peptides with therapeutic payloads to potentially improve treatment specificity while reducing off-target effects. This class of therapy has drawn growing interest across the biotech sector for its ability to deliver treatments more precisely to intended tissues or cell types.

    The FDA’s clearance of the company’s IND application is a critical regulatory milestone, as it allows TwoStep to move its first-in-class candidate into human clinical trials. Receiving IND clearance means the agency has reviewed the company’s preclinical data and determined that it is reasonable to proceed with testing in people, a meaningful validation of the underlying science and safety data package assembled to date.

    With substantial new capital in hand and a clear regulatory pathway forward, TwoStep Therapeutics is now positioned to advance its peptide-drug conjugate platform through early-stage clinical development. Success in this arena could contribute to the broader momentum in peptide therapeutics, an area that continues to attract interest for its potential to create more targeted and effective treatment options across a range of conditions.

    As with all early-stage clinical programs, it will take time before the full potential of this candidate is understood through the clinical trial process. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: TwoStep Therapeutics Announces Oversubscribed $62.5 Million Series A Financing and FDA Clearance of IND for First-in-Class Peptide-Drug Conjugate – SynBioBeta

  • New Phase I Trial Launches for Novel WRN-Targeting Peptide-Based Therapy in Advanced Cancers

    New Phase I Trial Launches for Novel WRN-Targeting Peptide-Based Therapy in Advanced Cancers

    A new first-in-human clinical trial has begun evaluating VVD-133214, an investigational oral therapy designed to target the Werner (WRN) protein in patients with advanced solid tumors that are microsatellite instability (MSI) high and/or deficient mismatch repair (dMMR). This Phase I study represents an exciting step forward in precision oncology, as it explores a novel biological pathway that may help control the growth of these specific cancer types.

    The WRN protein has emerged as a promising target in cancer research because certain tumors—particularly those with MSI or dMMR characteristics—appear to rely on WRN for their survival and growth. By selectively acting on this protein, VVD-133214 is designed to interfere with the growth mechanisms of cancer cells while potentially sparing healthy tissue that doesn’t share the same vulnerability. This kind of targeted approach reflects the ongoing evolution of cancer treatment toward therapies that are more precisely matched to a tumor’s underlying biology.

    The trial is structured as a dose-escalation and dose-expansion study, meaning researchers will first determine safe and effective dosing levels before expanding to evaluate the drug’s potential anti-tumor activity in larger patient groups. Notably, the study will assess VVD-133214 not only as a standalone treatment but also in combination with two well-established cancer therapies: bevacizumab, an anti-angiogenic agent, and pembrolizumab, a checkpoint inhibitor immunotherapy. Testing combination approaches from an early stage reflects a thoughtful strategy that could accelerate the identification of effective treatment regimens for patients with limited options.

    This multicenter, open-label design allows researchers across multiple sites to gather comprehensive data on safety, pharmacokinetics, and early signals of efficacy in real-world clinical settings. For patients with MSI and dMMR advanced solid tumors—cancers that often present significant treatment challenges—the initiation of this trial offers a meaningful opportunity to access an innovative therapeutic approach while contributing to the broader scientific understanding of WRN-targeted treatments.

    As with all early-phase clinical research, it will take time before definitive conclusions can be drawn about the safety and effectiveness of VVD-133214. However, the launch of this study highlights the continued innovation in the field of precision oncology and the ongoing efforts to develop new tools in the fight against difficult-to-treat cancers. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors